BCP
CRL icon

Blue Chip Partners’s Charles River Laboratories CRL Stock Holding History

Blue Chip Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,256
Closed -$357K – 166
2022
Q1 		$357K Buy
1,256
+49
+4% +$15.1K 0.04% 106
2021
Q4 		$455K Buy
1,207
+435
+56% +$169K 0.06% 100
2021
Q3 		$319K Buy
+772
New +$321K 0.04% 109

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Blue Chip Partners's CRL Position: Q2 2022 in Review

Blue Chip Partners sold out of Charles River Laboratories (CRL) in Q2 2022, closing a stake of 1,256 shares — an estimated $357K sold.

Blue Chip Partners first reported a position in CRL in Q3 2021 and held it in 3 quarters. The position peaked at $455K in Q4 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

  • Blue Chip Partners reported no remaining Charles River Laboratories position as of Q2 2022 after selling out during the quarter.
  • Blue Chip Partners sold 1,256 Charles River Laboratories shares in Q2 2022, an estimated $357K.
  • Blue Chip Partners first reported a position in Charles River Laboratories in Q3 2021 and held it in 3 quarters.
  • Blue Chip Partners's Charles River Laboratories position peaked at $455K in Q4 2021.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on Blue Chip Partners's 13F filing for Q2 2022, filed 1 Aug 2022.